Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 7/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103560 | 0.88 | CNR2 (0.39) | TP53KMT2AMEN1PKMCNR2 | |
| SCHEMBL5110851 | 0.84 | MAPT (0.36) | TP53KMT2AMEN1PKMCNR2 | |
| SCHEMBL6299933 | 0.81 | AAK1 (0.37) | TP53CNR2CNR1F2POLB | |
| SCHEMBL31069471 | 0.74 | POLB (0.46) | KMT2AF2HDAC1POLBLMNA | |
| SCHEMBL5109494 | 0.73 | TBXA2R (0.38) | CNR2CNR1F2 | |
| SCHEMBL20529246 | 0.70 | MAOB (0.43) | KMT2AMEN1 | |
| SCHEMBL2031499 | 0.70 | ALDH1A1 (0.42) | POLB | |
| SCHEMBL8293951 | 0.70 | POLB (0.66) | TP53KMT2AMEN1PKMPOLB | |
| SCHEMBL18954528 | 0.69 | MAOB (0.41) | — | |
| SCHEMBL7371826 | 0.68 | USP14 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092912-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors | NEUROGEN CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092912-A1 | Heteroaryl fused aminoalkyl-imidazole derivatives: selective modulators of GABAa Receptors | GABRA1, GABRB1, GABRA4 | TP53 4458/4885KMT2A 1325/4885MEN1 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.